Our top pick for
Pyxis Oncology, Inc. is a biotechnology business based in the US. Pyxis Oncology shares (PYXS) are listed on the NASDAQ and all prices are listed in US Dollars. Pyxis Oncology employs 38 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$11.77|
|52-week range||$11.72 - $19.00|
|50-day moving average||$12.60|
|200-day moving average||$12.60|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||-0.08%|
|1 month (2021-09-15)||N/A|
|3 months (2021-07-15)||N/A|
|6 months (2021-04-15)||N/A|
|1 year (2020-10-15)||N/A|
|2 years (2019-10-15)||N/A|
|3 years (2018-10-15)||N/A|
|5 years (2016-10-15)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$374.2 million|
TTM: trailing 12 months
We're not expecting Pyxis Oncology to pay a dividend over the next 12 months.
Pyxis Oncology, Inc. , a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.